Caissa Capital Management ltd., 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 14,426 shares at $4.14 ($56K) on 2023-06-09, disclosed to the SEC on 2023-06-09.
Open-market purchase of $56k AVTX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.49 | 2,984 | $10K | 18.5% |
| 2 | $3.93 | 6,398 | $25K | 44.5% |
| 3 | $4.14 | 5,044 | $21K | 37.0% |
| Total | $3.91 avg | 14,426 | $56K | 100% |
| Filing → |
| AVTX | BUY | 2023-06-14 | $64K | — | Filing → |
| AVTX | BUY | 2023-06-02 | $2K | — | Filing → |
| AVTX | BUY | 2023-05-30 | $7K | — | Filing → |